<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108676</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-I-111</org_study_id>
    <nct_id>NCT04108676</nct_id>
  </id_info>
  <brief_title>Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects</brief_title>
  <official_title>a Single-center, One-arm, Open, and Fixed Sequences Study to Evaluate the Effects of Omeprazole on the Pharmacokinetics of Fluzoparib in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Effect of Omeprazole on the Pharmacokinetics of
      Fluzoparib in Healthy male Adults.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2019</start_date>
  <completion_date type="Anticipated">November 19, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>repeated oral doses of Omeprazole on the pharmacokinetic profile of a single dose of Fluzoparib</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Fluzoparib:</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From 0 to t of Fluzoparib:</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From 0 to infinity of Fluzoparib:</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>AUC0-∞ (if available)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety in terms of Adverse Events Assessments</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>Adverse Events Assessments (NCI-CTC AE 5.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Fluzoparib Drug: Omeprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluzoparib</intervention_name>
    <description>PARP inhibitor</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>proton pump inhibitor</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 50 years (including both ends), male;

          2. Male volunteers have a body weight ≥ 50.0 kg and a body mass index (BMI) between 19
             and 28 kg/m2 (including both ends);

          3. Male volunteers are willing to have no birth plans in the next 6 months and
             voluntarily take effective contraceptive measures;

          4. Volunteers voluntarily sign written informed consent.

        Exclusion Criteria:

          1. Previous or currently suffering from circulatory system (myocarditis, coronary heart
             disease, pathological arrhythmia, stroke, etc.), endocrine system, nervous system,
             digestive system (peptic ulcer, colitis, pancreatitis, etc.), respiratory system
             (Invasive lung disease, pneumonia, dyspnea, etc., urogenital system (chronic kidney
             disease, renal insufficiency, renal anemia), hematology, immunology, psychiatry and
             metabolic abnormalities, etc. Result of any other disease;

          2. A history of allergies to drugs, foods or other substances; allergies, including a
             history of severe drug allergies or drug allergies; a history of allergies to
             Fluzoparib capsules or omeprazole magnesium enteric-coated tablets

          3. Those who have undergone surgery within 4 weeks prior to the trial or who plan to
             undergo surgery during the study;

          4. Those who have taken any drugs or health care products (including Chinese herbal
             medicines) within 14 days before the test;

          5. Any drug that inhibits or induces liver metabolism of the drug within 30 days prior to
             the test (eg, inducer - barbiturate, carbamazepine, phenytoin, glucocorticoid,
             omeprazole; inhibitor - SSRI resistance) Depressants, cimetidine, diltiazem,
             macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones,
             antihistamines;

          6. Those who participated in any clinical trial and took any clinical trial drug within 3
             months prior to the trial;

          7. Donate blood or massive blood loss (≥200 mL), receive blood transfusion or use blood
             products within 3 months before enrollment;

          8. One or more non-pharmaceutical contraceptives cannot be used during the volunteer
             trial;

          9. Those who have special requirements for diet and cannot follow the unified diet;

         10. Drink excessive amounts of tea, coffee and/or caffeinated beverages (8 cups or more, 1
             cup = 250 mL) per day;

         11. smokers or smokers with more than 5 cigarettes per day for the first 3 months of the
             trial or who cannot stop using any tobacco products during the trial period;

         12. Alcoholics or those who regularly drink alcohol within 6 months prior to the test, ie
             drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of
             40% alcohol or 150 mL of wine) or during the test period Stop using any alcoholic
             products;

         13. Drug abusers or soft drugs (eg marijuana) 3 months prior to the trial or hard drugs
             (eg cocaine, phencyclidine, etc.) 1 year prior to the trial; and nicotinic positive
             volunteers

         14. Abnormal vital signs (systolic blood pressure &lt;90 mmHg or &gt;140 mmHg, diastolic blood
             pressure &lt;50 mmHg or &gt;90 mmHg; pulse &lt;50 bpm or &gt;100 bpm) or physical examination,
             electrocardiogram, laboratory examination, imaging examination abnormalities
             Clinically significant (subject to the judgment of the clinical research doctor);

         15. have a history of dysphagia or any history of gastrointestinal disease that affects
             drug absorption;

         16. Those who have undergone any surgery within the first 6 months of screening; have
             previously undergone any surgery that affects gastrointestinal absorption (including
             gastrectomy, bowel resection, stomach reduction surgery, etc.);

         17. The volunteer refused to discontinue any beverage containing methylxanthine, such as
             caffeine (coffee, tea, cola, chocolate, etc.) or alcoholic beverages or any juice, 48
             hours before the study drug was administered until the end of the study;

         18. Creatinine clearance (CLCr) &lt;80 mL/min, or creatinine above the upper limit of normal;

         19. Volunteers may not be able to complete the study for other reasons or those the
             investigator believes should not be included.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoping Yang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The third xiangya hospital Hospital,of central south university</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

